BOOK
Cardiovascular Rheumatic Diseases, An Issue of Rheumatic Disease Clinics, E-Book
(2014)
Additional Information
Book Details
Abstract
Chronic joint pain is often associated with rheumatic diseases, but rheumatic diseases can also cause damage to vital organs including the heart. This articles in this issue will cover cardiac involvement in a variety of rheumatic diseases with discussions abotu clinical presentations and mechanistic aspects.
Table of Contents
| Section Title | Page | Action | Price |
|---|---|---|---|
| Front Cover | Cover | ||
| Cardiovascular Rheumatic Diseases\r | i | ||
| Copyright\r | ii | ||
| Contributors | iii | ||
| Contents | v | ||
| Rheumatic Disease Clinics\rOf North America\r | viii | ||
| Foreword | ix | ||
| Preface | xi | ||
| The Heart in Inflammatory Myopathies | 1 | ||
| Key points | 1 | ||
| Introduction | 1 | ||
| Methods | 2 | ||
| Results | 3 | ||
| Cardiomyopathies: Myocarditis | 3 | ||
| Cardiomyopathies: Structural/Electrophysiologic Abnormalities | 4 | ||
| CAD and Cerebral Vascular Disease | 5 | ||
| Cardiovascular Risk Factors | 5 | ||
| Laboratory Testing for Cardiac Involvement | 6 | ||
| Cardiac Symptoms and Outcomes | 6 | ||
| Treatments | 7 | ||
| Summary | 8 | ||
| References | 9 | ||
| The Heart in Vasculitis | 11 | ||
| Key points | 11 | ||
| Introduction | 11 | ||
| Large-vessel vasculitis | 12 | ||
| Takayasu Arteritis | 12 | ||
| Giant Cell Arteritis | 15 | ||
| Medium-vessel vasculitis | 15 | ||
| Polyarteritis Nodosa | 15 | ||
| Small-vessel vasculitis | 17 | ||
| Eosinophilic Granulomatosis with Polyangiitis | 17 | ||
| Granulomatosis with Polyangiitis and Microscopic Polyangiitis | 18 | ||
| Cryoglobulinemic Vasculitis | 18 | ||
| Variable-size vasculitis | 19 | ||
| Behcet’s Disease | 19 | ||
| Summary | 20 | ||
| References | 21 | ||
| Cardiovascular Disease in Rheumatoid Arthritis | 27 | ||
| Key points | 27 | ||
| Introduction | 27 | ||
| Cardiac disease as an extra-articular manifestation of RA | 28 | ||
| Pericarditis | 28 | ||
| Valvular Heart Disease | 28 | ||
| Myocardial Disease | 29 | ||
| Myocardial Dysfunction Related to RA Medication | 30 | ||
| Cardiac Amyloidosis | 31 | ||
| Coronary Arteritis | 31 | ||
| Atherosclerotic disease in RA | 31 | ||
| Traditional Risk Factors for CVD in RA | 32 | ||
| Dyslipidemia | 32 | ||
| HTN | 33 | ||
| Insulin resistance | 34 | ||
| Age | 34 | ||
| Body mass index | 34 | ||
| Smoking | 35 | ||
| Cardiovascular Risk Factors Associated with RA | 35 | ||
| Disease duration and its impact on CVD | 35 | ||
| Seropositivity and presence of shared epitope | 35 | ||
| Inflammation as a risk factor for atherosclerosis | 36 | ||
| Role of medications in cardiovascular risk in RA | 36 | ||
| NSAIDs | 36 | ||
| Glucocorticoids | 37 | ||
| Risk Assessment for CVD in RA | 37 | ||
| Management of Cardiovascular Risks in Patients with RA | 38 | ||
| Cardiovascular Risk Reduction by Disease Control | 39 | ||
| Summary | 39 | ||
| References | 39 | ||
| Cardiac Manifestations of Systemic Lupus Erythematosus | 51 | ||
| Key points | 51 | ||
| Neonatal lupus and congenital heart block | 51 | ||
| Pericarditis | 52 | ||
| Myocarditis and cardiomyopathy | 53 | ||
| CAD | 54 | ||
| Valvular disease | 55 | ||
| Summary | 56 | ||
| References | 56 | ||
| The Heart and Pediatric Rheumatology | 61 | ||
| Key points | 61 | ||
| Kawasaki disease | 61 | ||
| Diagnosis | 62 | ||
| Pathophysiology | 63 | ||
| Management | 65 | ||
| Prognosis | 66 | ||
| Acute rheumatic fever | 67 | ||
| Epidemiology | 67 | ||
| Pathogenesis of Carditis in ARF | 68 | ||
| Diagnosis of ARF | 69 | ||
| Cardiac Manifestations of ARF | 70 | ||
| Treatment of Carditis | 71 | ||
| Prevention | 72 | ||
| Poststreptococcal reactive arthritis | 72 | ||
| Clinical Presentation | 72 | ||
| Neonatal lupus erythematosus | 73 | ||
| Juvenile dermatomyositis | 75 | ||
| Ehlers-Danlos syndromes | 76 | ||
| Marfan syndrome | 76 | ||
| Systemic juvenile idiopathic arthritis | 77 | ||
| References | 78 | ||
| Systemic Sclerosis and the Heart | 87 | ||
| Key points | 87 | ||
| Introduction | 87 | ||
| Incidence and prognosis | 89 | ||
| Myocardial disease | 89 | ||
| Myocardial Fibrosis and Ventricular Diastolic Dysfunction | 90 | ||
| Ventricular Systolic Dysfunction | 92 | ||
| Myositis and Myocarditis | 93 | ||
| Pericardial disease | 93 | ||
| Acute and Chronic Pericarditis | 94 | ||
| Conduction disease and dysrhythmias | 94 | ||
| Vascular disease and less common manifestations | 95 | ||
| Diagnostic evaluation | 97 | ||
| Future directions and summary | 98 | ||
| References | 98 | ||
| Pulmonary Arterial Hypertension Related to Connective Tissue Disease | 103 | ||
| Key points | 103 | ||
| Introduction and definition | 103 | ||
| Classification of PH | 104 | ||
| Pathogenesis | 104 | ||
| Clinical presentation | 106 | ||
| Diagnosis | 107 | ||
| Screening | 107 | ||
| Confirmation | 107 | ||
| Severity and Prognosis | 108 | ||
| Etiology | 108 | ||
| Diagnostic workup in CTD APAH | 109 | ||
| PH in CTD | 109 | ||
| Scleroderma | 110 | ||
| SLE | 111 | ||
| Sjogren syndrome | 111 | ||
| Rheumatoid arthritis | 111 | ||
| MCTD | 111 | ||
| Polymyositis/dermatomyositis | 112 | ||
| Treatment | 112 | ||
| Prostacyclin analogues | 112 | ||
| Endothelin-receptor antagonists | 114 | ||
| Phosphodiesterase 5 inhibitors | 115 | ||
| Investigational agents | 115 | ||
| Tyrosine Kinase Inhibitors | 115 | ||
| Guanylate Cyclase Stimulators | 116 | ||
| NO | 116 | ||
| Combination of drug groups | 116 | ||
| Lung transplantation | 117 | ||
| Summary | 117 | ||
| References | 118 | ||
| Gout and the Heart | 125 | ||
| Key points | 125 | ||
| Introduction | 125 | ||
| Association between gout and CVD | 128 | ||
| Case Series and Cross-sectional Studies | 128 | ||
| Case-control and Cohort Studies | 128 | ||
| Association between gout and congestive heart failure | 135 | ||
| Association between gout and other CVD risk factors | 135 | ||
| Gout medications and CVD outcomes | 135 | ||
| Potential pathophysiologic pathways | 139 | ||
| Public health significance and summary | 140 | ||
| References | 141 | ||
| Index | 145 |